Cargando…
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes
METHODS: 40 individuals with type 1 diabetes (average age of 44.7 ± 2.5 years) were randomized into four groups: (1) control (placebo), (2) empagliflozin 25 mg daily, (3) metformin 2000 mg daily, and (4) empagliflozin-metformin combination (25 mg and 2000 mg daily, respectively). At inclusion and af...
Autores principales: | Janić, Miodrag, Cankar, Matej, Šmid, Jan, France Štiglic, Alenka, Jerin, Aleš, Šabovič, Mišo, Janež, Andrej, Lunder, Mojca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9130013/ https://www.ncbi.nlm.nih.gov/pubmed/35620570 http://dx.doi.org/10.1155/2022/6796470 |
Ejemplares similares
-
Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
por: Lunder, Mojca, et al.
Publicado: (2018) -
Arterial Stiffness and Cardiovascular Therapy
por: Janić, Miodrag, et al.
Publicado: (2014) -
A Low-Dose Combination of Fluvastatin and Valsartan: A New “Drug” and a New Approach for Decreasing the Arterial Age
por: Janić, Miodrag, et al.
Publicado: (2015) -
Treating Arterial Ageing in Patients with Diabetes: From Mechanisms to Effective Drugs
por: Lunder, Mojca, et al.
Publicado: (2021) -
Associations among different functional and structural arterial wall properties and their relations to traditional cardiovascular risk factors in healthy subjects: a cross-sectional study
por: Lunder, Mojca, et al.
Publicado: (2012)